Removal of Remdesivir's Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19.
Antimicrob Agents Chemother
; 64(11)2020 10 20.
Article
in English
| MEDLINE | ID: covidwho-738379
ABSTRACT
Remdesivir has reported efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro and in vivo Drug-drug interactions limit therapeutic options in transplant patients. Remdesivir and its metabolite GS-441524 are excreted principally in urine. In intensive care unit (ICU) settings, in which multiple-organ dysfunctions can occur rapidly, hemodialysis may be a viable option for maintaining remdesivir treatment, while improving tolerance, by removing both remdesivir's metabolite (GS-441524) and sulfobutylether ß-cyclodextrin sodium (SEBCD). Additional studies may prove informative, particularly in the evaluations of therapeutic options for coronavirus disease 2019 (COVID-19).
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Pneumonia, Viral
/
Pyrroles
/
Triazines
/
Adenosine Monophosphate
/
Coronavirus Infections
/
Beta-Cyclodextrins
/
Alanine
/
Betacoronavirus
/
Furans
Type of study:
Experimental Studies
Language:
English
Year:
2020
Document Type:
Article
Affiliation country:
AAC.01521-20
Similar
MEDLINE
...
LILACS
LIS